PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 1000 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.
Our mission is to create customer satisfaction and foster long-term customer loyalty through excellence in peptide technology, quality, value, service and customer support.
Our goal is to assist our clients at every step of product development; from early stage development to commercial GMP grade manufacturing.
Our customers are our focus. We strive to be your preferred partner from simple to complex peptide manufacturing by consistently providing you with the highest quality products and services.